Promising early stage clinical trial results for three next-generation CFTR modulator therapies that target the underlying defect in cystic fibrosis were announced. The studies, led by Vertex Pharmaceuticals Inc., highlight
Researchers are making amazing progress in drug development — there will be more cystic fibrosis-related clinical trials in 2016 than ever before. Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the CF
ORKAMBI IS FDA APPROVED! THIS IS what your money is doing for those living with Cystic Fibrosis! The FDA approved a combination drug (lumacaftor/ivacaftor – Orkambi™) – on July 2!